tbuckley/cabot-search huggingface dataset:
PATH-01. IDENTIFICATION OF PROGNOSTIC VARIABLES BASED ON MOLECULAR PROFILING OF LONG-TERM AND SHORT-TERM SURVIVING GLIOBLASTOMA PATIENTS
Authors: Signe Regner Michaelsen, Thomas Urup, Lars Rønn Olsen, Linn Gillberg, Helle Broholm, Kirsten Grunnet, Kirsten Grønbæk, Petra Hamerlik, Ulrik Lassen, Hans Skovgaard Poulsen
Journal: Neuro-Oncology (2017)

Glioblastoma is a devastating disease and despite extensive treatment, overall survival (OS) for these patients remains poor. Yet, a small proportion of glioblastoma patients present relatively long survival over 3 years, but the underlying molecular background separating these long-term survivors (LTS) from short-term survivors (STS) are still insufficiently understood. The purpose of this study was to identify independent prognostic variables for survival by examining molecular profiles of LTS and STS in a clinically well characterized cohort of glioblastoma patients. The cohort consisted of 93 patients diagnosed with primary glioblastoma and treated with radiation therapy plus concomitant and adjuvant chemotherapy as well as bevacizumab administered in the first-line setting or at time of recurrence. Among these, 14 STS (OS<12 months) and 6 LTS (OS>36 months) were identified, which were all confirmed being IDHwt. For all patients, RNA had previously been purified from microdissected tumor tissue of the diagnostic specimen and analyzed for expression levels by a customized NanoString platform. This covered 800 genes related to glioblastoma cancer hallmarks, including regulation of angiogenesis and immune response. When comparing expression of these genes in LTS vs. STS using a Welsh’s t-test, 14 candidate genes ended up significant (P<0.05). These candidate genes are being tested in multivariate analysis together with known clinical prognostic factors such as age, performance status, corticosteroid use and MGMT promoter methylation, to test if they represent independent prognostic variables. Dependent on results, prognostic models will be generated able to predict survival probability for individual patients and thereby identify patients likely to become LTS. Updated results will be presented.
SURG-11. LASER INTERSTITIAL THERMOTHERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: ASSOCIATION BETWEEN TIME TO INITIATION OF CHEMOTHERAPY POST-PROCEDURE AND OUTCOME
Authors: Stefania Maraka, Dhiego Chaves De Almeida Bastos, Barbara J O’Brien, Diane Liu, Olga Starostina, Kristin Alfaro-Munoz, Ganesh Rao, John de Groot, Sujit S Prabhu
Journal: Neuro-Oncology (2017)

LITT is used for cytoreduction of unresectable glioblastoma and is associated with blood brain barrier disruption with an increased permeability peak at 2 weeks. We investigated if time to initiation of chemotherapy post-LITT was associated with progression free survival (PFS) and overall survival (OS). Records of glioblastoma patients who underwent LITT at our institution between 2013-2017 were reviewed. Patients with inadequate follow-up or no further treatment after LITT were excluded. A time-to-event analysis was performed to investigate the association between PFS, OS and the time to initiation of chemotherapy after LITT. The study included 21 patients; 17 recurrent glioblastoma (rGBM) (6 secondary glioblastoma), 4 newly diagnosed glioblastoma (nGBM). Median age was 53.6 (19.8-64.9) years. Three patients (14%) had isocitrate dehydrogenase (IDH)-1 mutation by immunohistrochemistry and two patients had unknown IDH status. Pre- and post-operative median KPS were 90 (60-100) and 80 (40-100) respectively. Eleven patients had difficulty weaning steroids (4 patients initiated steroids peri-operatively, 7 patients prior to surgery). For rGBM post-LITT median PFS was 3.36 months (95% CI (0.21, 0.51)) and median OS was 18.48 months (95% CI (0.66,NA)) with 5 deaths. Median PFS and OS for nGBM has not been reached. Eighteen patients (86%) received post-LITT chemotherapy of which eight initiated treatment >3 weeks post-LITTdue to poor functionality (6), pregnancy (1), and patient choice (1). Among the patients receiving chemotherapy, time to initiation of chemotherapy was not associated with PFS or OS. Chemotherapy in rGBM cohort included lomustine (6), temozolomide (5), bevacizumab (3), bevacizumab + lomustine (1), lapatinib (1), and Novo-TTF (1). Median time to initiation ofi bevacizumab (4 patients) after LITT was 30.5 (17-45) days, without complications. LITT may be an effective cytoreductive treatment for glioblastoma. Timing of onset of chemotherapy after LITT for glioblastoma is not associated with PFS or OS.
Vigilancia de la tos ferina en Suiza, 1992 a 1997: una epidemia importante en 1994. ¿Qué nos depara el futuro?
Authors: H. C. Matter
Journal: Eurosurveillance (1999)

Desde junio de 1991, la Red Suiza de Vigilancia Centinela ‘Sentinella’ (SSSN) registra casos de tos ferina para monitorizar la tendencia de esta enfermedad en Suiza y evaluar la estrategia de vacunacion en vigor (1,2). La red Sentinella consta de unos 200 medicos generales, especialistas en medicina interna y pediatras del sector privado que declaran semanal y voluntariamente los datos de morbilidad a la Oficina Federal Suiza de Sanidad (SFOPH). Los medicos participantes representan alrededor del 3,5% de todos los medicos menores de 65 anos en cada una de las tres especialidades en Suiza.
P2.17-002 Pulmonary and Mediastinal Paragangliomas: Rare Endothoracic Malignancies with Challenging Diagnosis and Treatment
Authors: A. De Palma, M. Lorusso, F. Di Gennaro, O. Pizzuto, G. Garofalo, A. Fiorella, E. Maiolino, G. Nex, M. Schiavone, A. Gentile, G. Lastilla, L. Resta, M. Loizzi
Journal: Journal of Thoracic Oncology (2017)
P3.02-042 DS-1205b, a Novel, Selective, Inhibitor of AXL, Delays the Onset of Resistance and Overcomes Acquired Resistance to EGFR-TKIs
Authors: T. Jimbo, T. Taira, T. Komatsu, K. Kumazawa, N. Maeda, N. Haginoya, T. Suzuki, M. Ota, Y. Totoki, C. Wada, K. Inaki, T. Isoyama, M. Uno
Journal: Journal of Thoracic Oncology (2017)
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab
Authors: M. Puzzoni, L. Demurtas, R. Giampieri, P. Ziranu, V. Pusceddu, A. Mandolesi, C. Cremolini, G. Masi, F. Gelsomino, C. Antoniotti, C. Loretelli, F. Meriggi, A. Zaniboni, A. Falcone, S. Cascinu, M. Scartozzi
Journal: Annals of Oncology (2017)
TMIC-05. THE DURA MATER MODULATES THE SURROUNDING MICROENVIRONMENT TO PROMOTE TUMOR GROWTH AND IMMUNE EVASION
Authors: Alexandra Calinescu, Katrina Clines, Hyun Sik Moon, Russell Taichman, Catherine Van Poznak, Gregory Clines, Nicholas Szerlip
Journal: Neuro-Oncology (2017)

The dura mater, the outer layer of the protective meninges, lies adjacent to the skull and vertebral bones, and, at specific sites, in direct contact with the bone marrow (BM). During development, the dura regulates morphogenesis in the CNS and bone, secreting factors which promote proliferation, migration and differentiation of precursor cells. Hence, the dura actively modulates the environment of neighboring tissues. The CNS has long been considered an immune privileged environment, with stunted immune responses attributed to the presence of the blood brain barrier, the lack of lymphatic vessels within the parenchyma and to low levels of MHC molecules. It is possible that cytokines from the dura modulate the surrounding environment to protect the CNS from damaging inflammation whilst promoting a favorable environment for tumor growth, acting directly on tumor cells and indirectly on the adjacent BM to induce an immunosupression. To begin to test this hypothesis we cultured dural fibroblasts in the presence or absence of prostate and breast carcinoma cells, known to frequently metastasize to the spine, and show that in the presence of carcinoma cells, dural fibroblasts increase expression of several chemokines known to promote cancer progression and metastasis (CXCL1, CXCL5, CXCL12, CCL2). Furthermore, conditioned media from the dura (DCM) increased proliferation, migration and invasion of carcinoma cells. In addition, DCM induced proliferation of BM-cells, most prominently of CD11b+Gr1neg myeloid cells and increased expression of immunosupressive molecules: Arginase 1, CD206, TGFbi, TGFBRII. We propose that the dura represents an important component which modulates the surrounding environment. Ongoing experiments are testing the individual contribution of secreted factors from the dura on promoting malignancy and tumor immune evasion. Identifying the molecular components which originate in the dura and promote tumor dissemination and growth will allow for the development of new targets for therapeutic intervention.
Transforming growth factor-β1 decreases epithelial tight junction integrity in chronic rhinosinusitis with nasal polyps
Authors: Jian Jiao, Ming Wang, Su Duan, Yifan Meng, Na Meng, Ying Li, Erzhong Fan, Cezmi A. Akdis, Luo Zhang
Journal: Journal of Allergy and Clinical Immunology (2017)
P2.17-003 Is Complete Resection Mandatory for Mediastinal Germ Cell Tumor Which Shows Severe Adhesion to Greater Vessels?
Authors: H. Ito, H. Nakayama, T. Nagashima, J. Samejima, J. Osawa, K. Inafuku, M. Nito, K. Yamada, T. Yokose
Journal: Journal of Thoracic Oncology (2017)
¿Cumple la vigilancia de las ITS en Inglaterra los requisitos del siglo XXI? Evaluación de los datos de la región del sudoeste
Authors: C Ihekweazu, N Maxwell, S Organ, I Oliver
Journal: Eurosurveillance (2007)

En este estudio se examino la capacidad de dos sistemas de vigilancia de las infecciones de transmision sexual (ITS) para proporcionar una informacion pertinente, precisa y oportuna con respecto a las actividades de prevencion y control en Inglaterra, empleando datos del sudoeste, la mas grande de las nueve regiones del pais.
QLIF-28. FATIGUE IN PATIENTS WITH LOW GRADE GLIOMA
Authors: Ellen van Coevorden- van Loon, Marijke B Coomans
Journal: Neuro-Oncology (2017)

Fatigue is the most prevalent and disabling symptom in cancer patients. Fatigue is even the most important cause of loss of quality of life both for the patient and the care giver. Cancer-related fatigue is defined as a “persistent, subjective sense of tiredness related to cancer and cancer treatment that interferes with usual functioning”. Scientific literature on this topic is scarce and reports disparate results. This study systematically reviews how fatigue is assessed in patients with low-grade glioma and evaluates its prevalence in LGG patients. A systematic literature search was performed in PubMed, Embase and PsychINFO for articles reporting on fatigue in patients with LGG. Inclusion criteria were: 1) adult patients with LGG and 2) fatigue was assessed as primary or secondary outcome measure. In total, 19 articles were selected, including 971 patients. Seven self-assessment instruments were identified. Prevalence rates ranged from 39% to 77%. Fatigue was found to be a common side effect of treatment. The prevalence rates ranged from 20% to 76% when fatigue was reported as a mild or moderate side effect and fatigue was prevalent in 4% when reported as a severe side effect. Despite the growing awareness of cancer-related fatigue, there is still a lack of knowledge of the exact pathophysiology of fatigue and the underlying mechanisms of fatigue in LGG patients. This review shows that fatigue is a common problem in LGG patients. It must be taken into account that even multidimensional fatigue instruments not yield insufficient insight in potential causes or consequences of fatigue, like a decrease in physical and cognitive performance. We suggest research to analyse the factors of fatigue in low grade patients with subjective and objective measurement outcomes to developing individualized (rehabilitation) treatment programs in LGG patients.
OA 09.01 Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation Sequencing
Authors: Z. Piotrowska, R. Nagy, S. Fairclough, R. Lanman, N. Marcoux, S. Gettinger, T. Owonikoko, S. Ramalingam, L. Sequist
Journal: Journal of Thoracic Oncology (2017)
GENE-09. COMPREHENSIVE GENETIC ALTERATION PROFILING IN PRIMARY AND RECURRENT GLIOBLASTOMA
Authors: Beth Neilsen, Richard Sleightholm, Rodney McComb, Benjamin McGahan, Michele Aizenberg
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is known to be heterogeneous, but a knowledge gap exists regarding its genetic alterations and their influence on evolution, resistance, and therapeutic response. The FoundationOne® comprehensive genomic profile was utilized to analyze ten patients’ matched primary and recurrent GBM. The profile looks for mutations, indels, copy number alterations (CNAs), and rearrangements in 315 genes and 28 introns via next-generation sequencing (NGS). These alterations were further characterized as mutations with known/likely cancer-promoting function or variants of unknown significance. Patient clinical information was reviewed for associations with genetic alterations. Identified mutations in our cohort were compared with known mutations in GBM from the Catalogue Of Somatic Mutations in Cancer (COSMIC). All tumors demonstrated genetic alterations between the primary and recurrence including one which was resected without intervening therapy. This suggests that time and/or therapeutic intervention contribute to genetic alterations in GBM. Although there were mutations common to both the primary and recurrence, the percent reads between the two often varied substantially suggesting clonal expansion and contraction. For example, EGFR mutations were significantly expanded in three patients, and CNAs were increased in two patients at recurrence. Four genes were commonly altered in primary and recurrent GBM and were more prevalent in our cohort than in the COSMIC database: CDKN2A (86% vs 53%) and CDKN2B (86% vs 54%) deletion, EGFR activating mutation (52% vs 10%) or amplification (81% vs 45%), and TERT mutation (95% vs 51%). Lastly, PI3K pathway activating mutations were also commonly seen in our cohort (67%). NGS revealed that GBM changed over time and with treatment. Mutations in TERT, CDKN2A/CDKN2B, EGFR, and PI3K pathway were commonly observed in both primary and recurrent GBM revealing their prognostic and therapeutic potential. This may have important implications for individualized therapies and may be evaluated with a larger cohort.
P2.01-004 Safety and Efficacy of Nab-Paclitaxel plus Carboplatin in Elderly Patients with NSCLC (ABOUND.70+)
Authors: C. Langer, E. Anderson, R. Jotte, J.W. Goldman, D. Haggstrom, D. Smith, C. Dakhil, K. Konduri, E. Kim, T.J. Ong, A. Sanford, K. Amiri, J. Weiss
Journal: Journal of Thoracic Oncology (2017)
NCOG-19. NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION
Authors: Martin Klein, Jaap C Reijneveld, Ahmed Idbaih, Alba Brandes, Walter Taal, Paul M Clement, Julien Domont, Mario Campone, Martin J B Taphoorn, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Vassilis Golfinopoulos, Michael Platten, Thierry Gorlia, Martin van den Bent, Wolfgang Wick
Journal: Neuro-Oncology (2017)

Despite prolonged PFS, EORTC study 26101 showed that combined treatment of lomustine (LOM) plus bevacizumab (Bev) does not confer an OS advantage over LOM alone. Here we report in detail the outcomes on neurocognitive functioning (NCF) of these patients. NCF using Hopkins Verbal Learning Test (Free Recall, Delayed Recall, and Delayed Recognition), Trail Making Test (TMT A/B), and Controlled Oral Word Association Test (COWA) was evaluated at baseline and every 12 weeks. Minimal compliance for analyses was set at 60%. The Reliable Change Index (RCI) was calculated for each test outcome to define NCF change over time. NCF assessment was performed at baseline in 288 LOM+Bev patients and 149 LOM patients (randomization ratio 2:1). Compliance in both arms dropped from 94.5% at baseline to 61.4% at week 36. The primary analysis compared NCF scores at last disease assessment before or at 36 weeks in patients who had at least one NCF assessment after baseline between treatment arms. No statistically significant differences were found at baseline and follow-up in NCF between treatment arms and the RCI was not indicative for a clinically significant neurocognitive decline over time in a specific treatment arm. Poorer NCF was significantly correlated with poorer overall health, quality of life, and WHO performance status. Poorer NCF outcome was also associated with steroid use at baseline and tumors >40 mm. Except for TMT-A and TMT-B, NCF tended to be lower in patients with first reported target lesion in the left hemisphere. NCF in all domains were significantly linked to OS in univariate, but not in multivariate Cox regression analyses. NCF of patients with progressive glioblastoma using lomustine is similar to that of patients using lomustine plus bevacizumab and there is no evidence of accelerated NCF decline in either treatment regimen at the group level.
CBIO-28. PATIENT GBM CELL ORIGINATED SECRETOME ANALYSIS IDENTIFIES CYTOKINE A, AS A POTENT THERAPEUTIC TARGET
Authors: Suji Han, Kayoung Shin, Hyunju Kang, Jinku Lee, Dohyun Nam
Journal: Neuro-Oncology (2017)

GBM is the most aggressive human primary brain tumor and leads to poor clinical outcomes. According to previous studies, exogenous factors secreted from primary brain tumor cells can change the growth pattern of normal cells. We analyzed the ingredients of cell culture media from two patient glioblastoma cells which can grow without growth factors. As a result, we selected a significant factor for tumor cell growth which is called cytokine A, the Heparin-binding growth factor. Because of the cell viability maintenance ability of cytokine A, we tried to investigate detailed mechanism of cytokine A and applied the result to the combination therapy. Cytokine A is critical for tumorigenesis of GBM by modulating DNA damage signaling and cell cycle through ROS. For that reason, cytokine A is effective therapeutic target and can be used in combination therapy.
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
Authors: Monique B. Nilsson, Huiying Sun, Lixia Diao, Pan Tong, Diane Liu, Lerong Li, Youhong Fan, Alissa Poteete, Seung-Oe Lim, Kathryn Howells, Vincent Haddad, Daniel Gomez, Hai Tran, Guillermo Armaiz Pena, Lecia V. Sequist, James C. Yang, Jing Wang, Edward S. Kim, Roy S. Herbst, J. Jack Lee, Waun Ki Hong, Ignacio Wistuba, Mien-Chie Hung, Anil K. Sood, John V. Heymach
Journal: Science Translational Medicine (2017)

Chronic stress hormones promote EGFR inhibitor resistance in EGFR mutant non–small cell lung cancer.
P2.15-011 Therapeutic Strategies and Genetic Comparisons in SCLC and LCNEC of the Lung Using Next-Generation Sequencing
Authors: M. Ito, Y. Miyata, S. Hirano, S. Kimura, F. Irisuna, K. Kushitani, Y. Tsutani, Y. Takeshima, M. Okada
Journal: Journal of Thoracic Oncology (2017)
P1.01-051 Nivolumab Versus Chemotherapy as Post-Platinum Therapy for Advanced Non-Small Cell Lung Cancer in a Real-world Setting
Authors: M. Moezi, J. Chandler, D. Waterhouse, S. Wilks, D. Richards, M. Hussein, E. Garon, D. Spigel, V. Gunuganti, M. Danese, M. Gleeson, D. Lubeck, V. Burns, B. Korytowsky, C. Batenchuk, R. Jotte
Journal: Journal of Thoracic Oncology (2017)
From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial
Authors: O. Garrone, M.C. Cursano, C. De Angelis, T. Giarratano, C. Saggia, A. Beano, M. Cazzaniga, N. La Verde, A. Milani, E. Collovà, L. Coltelli, E. de Conciliis, A.M. Vandone, M. Airoldi, L. D'Onofrio, I. Bertolini, V. Guarneri, M. Donadio, F. Riva, M.C. Merlano
Journal: Annals of Oncology (2017)
JCES 01.10 The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
Authors: S. Xu, W. Zhong, Y. Zhang, W. Mao, L. Wu, Y. Shen, Y. Liu, C. Chen, Y. Cheng, L. Xu, J. Wang, K. Fei, X. Li, J. Li, C. Huang, Z. Liu, S. Xu, K. Chen, S. Xu, L. Liu, P. Yu, B. Wang, H. Ma, H. Yan, X. Yang, Y. Wu, Q. Wang
Journal: Journal of Thoracic Oncology (2017)
MA 02.02 Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
Authors: B. Levy, G. Giaccone, B. Besse, E. Felip, M. Garassino, M. Domine, P. Garrido, B. Piperdi, S. Ponce Aix, R. Slepetis, X. Wu, A. Fandi, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2017)
Viaggiatori di ritorno dalla Svezia, sentinelle per una valutazione comparativa dell'incidenza della patologia in altri paesi europei - esempi di infezione da Campylobacter e Giardia
Authors: K Ekdahl, J Giesecke
Journal: Eurosurveillance (2004)

E difficile ottenere figure confrontabili per la valutazione dell'incidenza della patologia tra diversi stati. Verra pertanto messo a confronto il rischio di infezione per gli svedesi in viaggio verso altri stati europei. Verra considerato come numeratore il numero di casi di infezioni da Campylobacter e Giardia, importati dagli stati europei e riportati nel database di sorveglianza nazionale svedese, e come denominatore il numero di visitatori in ogni stato ricavato da un database commerciale in cui vengono registrati i viaggi compiuti all'estero. E stato messo a confronto anche il rischio di infezione nei turisti rispetto alle figure di incidenza nazionale per un numero determinato di nazioni. Nell'arco di 7 anni, dal 1997 al 2003, sono stati diagnosticati 14.829 casi di infezione da Campylobacter e 1.112 casi di infezione da Giardia in soggetti svedesi di ritorno dagli stati europei. I dati sono stati ricavati da un database che contiene informazioni su 14.519 viaggi compiuti di notte in questi stati durante il periodo su indicato. Piu di 100 soggetti su un campione di 100.000 viaggiatori diretti verso il Portogallo e la Turchia hanno corso il rischio di infezione da Campylobacter e soltanto 1 viaggiatore diretto verso la Finlandia. Il rischio di giardiasi e superiore in Russia (50). In molti stati europei i casi di segnalazioni incomplete di infezione da Campylobacter sono ancora numerosi. E possibile concludere che il rischio di infezione da Campylobacter e Giardia varia molto in Europa. I turisti di ritorno nel proprio paese costituiscono la popolazione sentinella e pertanto un utile strumento per valutare le differenze, ancora notevoli e non spiegate, tra il rischio che corrono i viaggiatori e l'incidenza nazionale registrata.